Callan Family Office LLC Purchases Shares of 22,183 Fresenius Medical Care AG (NYSE:FMS)

Callan Family Office LLC purchased a new position in shares of Fresenius Medical Care AG (NYSE:FMS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,183 shares of the company’s stock, valued at approximately $502,000.

A number of other hedge funds have also made changes to their positions in FMS. Crossmark Global Holdings Inc. raised its position in shares of Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after acquiring an additional 23,692 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after buying an additional 4,800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fresenius Medical Care during the third quarter worth about $420,000. Moran Wealth Management LLC raised its stake in shares of Fresenius Medical Care by 47.0% during the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after purchasing an additional 74,621 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Fresenius Medical Care by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after acquiring an additional 2,233 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial raised their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $23.98 on Monday. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25. The stock has a market cap of $14.07 billion, a PE ratio of 19.82, a P/E/G ratio of 0.76 and a beta of 0.99. The firm has a 50-day moving average of $23.53 and a 200-day moving average of $22.05. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.